Rashtriya Newsflash

Urothelial Carcinoma – Pipeline Insight, 2026

DelveInsight’s “Urothelial Carcinoma – Pipeline Insight, 2026” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in the Urothelial Carcinoma pipeline landscape. It covers the Urothelial Carcinoma pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Urothelial Carcinoma treatment landscape. Learn more about the evolving Urothelial Carcinoma pipeline today @ https://www.delveinsight.com/sample-request/urothelial-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the Urothelial Carcinoma Pipeline Report

• DelveInsight’s Urothelial Carcinoma Pipeline Insight report depicts a robust space with 40+ active players working to develop 50+ pipeline therapies for Urothelial Carcinoma treatment.

• The most advanced pipeline candidate in Phase III clinical development is being progressed by Janssen Research and Development.

• Pemazyre (pemigatinib) by Incyte Corporation is a potent, selective, oral inhibitor of FGFR isoforms 1, 2 and 3, demonstrating selective pharmacologic activity against cancer cells with FGFR alterations, and is being evaluated in Urothelial Carcinoma.

• Cetrelimab by Janssen Research and Development is an investigational PD-1 monoclonal antibody being studied in the treatment of bladder cancer as a combination treatment.

• The leading Urothelial Carcinoma companies include Janssen Research and Development, MedPacto, AstraZeneca, Helsinn/QED Therapeutics, Inovio Pharmaceuticals, Abbisko Therapeutics, Bayer, 4D pharma plc, RemeGen, Infinity Pharmaceuticals, Kyowa Kirin, Inc., Ikena Oncology, Vyriad, Seagen, Pfizer, Incyte Corporation, Prestige BioPharma, TARIS Biomedical and others.

• Promising Urothelial Carcinoma therapies include Pemazyre (pemigatinib), Cetrelimab, Vactosertib, MV NIS and others.

Download for updates and the latest revolution in Urothelial Carcinoma care @ Urothelial Carcinoma Pipeline Report

Urothelial Carcinoma Emerging Drugs Profile

• Pemazyre (pemigatinib): Incyte Corporation

Pemazyre (pemigatinib) is a kinase inhibitor indicated in the United States for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. In Japan, Pemazyre is approved for the treatment of patients with unresectable biliary tract cancer (BTC) with an FGFR2 fusion gene, worsening after cancer chemotherapy. Pemazyre is a potent, selective, oral inhibitor of FGFR isoforms 1, 2 and 3 which, in preclinical studies, has demonstrated selective pharmacologic activity against cancer cells with FGFR alterations. The drug is currently being evaluated in clinical studies for Urothelial Carcinoma.

• Cetrelimab: Janssen Research and Development

Cetrelimab is a Janssen discovered and developed investigational programmed cell death receptor-1 (PD-1) monoclonal antibody being studied in the treatment of bladder cancer, prostate cancer, and multiple myeloma as a combination treatment. Cetrelimab is also being evaluated in multiple combination regimens across the Janssen oncology portfolio. It is the most advanced pipeline candidate in the Urothelial Carcinoma space and is currently in Phase III clinical development.

For more information on the Urothelial Carcinoma Emerging Drugs Profile, download DelveInsight’s comprehensive Urothelial Carcinoma Pipeline Insight report.

The Urothelial Carcinoma Pipeline Report Provides

• Detailed insights about companies developing therapies for Urothelial Carcinoma, with aggregate therapies developed by each company.

• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Urothelial Carcinoma treatment.

• Urothelial Carcinoma companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Urothelial Carcinoma drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company–company and company–academia), licensing agreements, and financing details for future advancement of the Urothelial Carcinoma market.

Learn more about Urothelial Carcinoma Drugs opportunities in our comprehensive Urothelial Carcinoma pipeline report @ Urothelial Carcinoma Unmet Needs

Urothelial Carcinoma Companies

There are 40+ key companies, such as Janssen Research and Development, MedPacto, AstraZeneca, Helsinn/QED Therapeutics, Inovio Pharmaceuticals, Abbisko Therapeutics, Bayer, 4D pharma plc, RemeGen, Infinity Pharmaceuticals, Kyowa Kirin, Inc., Ikena Oncology, Vyriad, Seagen, Pfizer, Incyte Corporation, Prestige BioPharma, TARIS Biomedical and others, developing therapies for Urothelial Carcinoma, with Janssen Research and Development having its Urothelial Carcinoma drug candidate in the most advanced Phase III stage.

DelveInsight’s Urothelial Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Intranasal

• Intrathecal

• Intravenous

• Oral

• Oral/Intravenous

• Parenteral

• Subcutaneous

• Subcutaneous/Intramuscular

• Transdermal

Urothelial Carcinoma products have been categorized under various Molecule types such as:

• Antisense oligonucleotide

• Gene therapy

• Hormones

• Neuropeptides

• Oligonucleotides

• Small Molecule

• Triglyceride

Discover the latest advancements in Urothelial Carcinoma treatment by visiting our website. Stay informed @ Urothelial Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Urothelial Carcinoma Pipeline Report

• Coverage: Global

• Urothelial Carcinoma companies: Janssen Research and Development, MedPacto, AstraZeneca, Helsinn/QED Therapeutics, Inovio Pharmaceuticals, Abbisko Therapeutics, Bayer, 4D pharma plc, RemeGen, Infinity Pharmaceuticals, Kyowa Kirin, Inc., Ikena Oncology, Vyriad, Seagen, Pfizer, Incyte Corporation, Prestige BioPharma, TARIS Biomedical and others

• Urothelial Carcinoma Therapies: Pemazyre (pemigatinib), Cetrelimab, Vactosertib, MV NIS and others

• Urothelial Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• Urothelial Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Table of Contents

1. Introduction

2. Executive Summary

3. Urothelial Carcinoma: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Urothelial Carcinoma – DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III)

8. Mid Stage Products (Phase II)

9. Early Stage Products (Phase I)

10. Preclinical and Discovery Stage Products

11. Inactive Products

12. Urothelial Carcinoma Key Companies

13. Urothelial Carcinoma Key Products

14. Urothelial Carcinoma Unmet Needs

15. Urothelial Carcinoma Market Drivers and Barriers

16. Urothelial Carcinoma Future Perspectives and Conclusion

17. Urothelial Carcinoma Analyst Views

18. Appendix

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services